NEW YORK and LONDON – Akari Therapeutics (NASDAQ:AKTX, is pleased to announce that Dr David Horn Solomon will be appointed as the company’s new chief executive officer (CEO), effective August 28, 2017.
“I am very pleased that David will be joining Akari and that we have been successful in attracting a person of his calibre, with over 20 years of leadership experience in the biotechnology industry,” said Ray Prudo, M.D., Executive Chairman of Akari. “David has a strong track record of leading Phase 2-stage companies like Akari. most notably, at Zealand Pharma where he led the development of lixisenatide, which is now commercialized by Sanofi.”
Akari is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by the dysregulation of complement C5 and/or leukotriene B4 (LTB4).
